• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 16, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

A new mechanism for neurodegeneration in a form of dementia

Bioengineer by Bioengineer
May 8, 2018
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Philadelphia, May 8, 2018 A new study in Biological Psychiatry reports that dementia-related and psychiatric-related proteins cluster together to form aggregates in the brain, leading to abnormal cell function and behavior. Aggregation of the protein TDP-43 is a hallmark of a pathological process that leads to dementia called frontotemporal lobar degeneration (FTLD). The study showed that as TDP-43 accumulates in the brain of patients with FTLD, it ropes in DISC1, an important protein in the pathology of many mental conditions.

The findings provide a clue to the unsolved puzzle of why psychiatric disorders often emerge in neurodegenerative disorders. "From the clinical point of view, it is critical to understand the molecular mechanisms underlying psychiatric symptoms in neurodegenerative diseases," said senior author Motomasa Tanaka, PhD, of RIKEN Brain Science Institute, Japan. The findings reveal that the TDP-43/DISC1 protein clusters disrupt the production of new proteins in neurons, a process critical for higher brain functions that are impaired in psychiatric disorders.

First author Ryo Endo, PhD, and colleagues found the co-aggregates in postmortem brain tissue from patients with FTLD and in a mouse model of FTLD. The FTLD model mice were hyperactive and displayed abnormal social interactions, behaviors relevant to multiple psychiatric conditions. Aggregation of the protein renders it unusable, so Dr. Endo and colleagues added DISC1 back into the mice. The behavioral abnormalities in the mice returned to normal.

"At the mechanistic level, TDP-43 and DISC1 co-aggregation disrupted activity-dependent local translation in dendrites," said Dr. Tanaka, a process that builds proteins from DNA codes based on neural activity. The disruption in translation resulted in reduced synaptic protein expression in the mice. Adding DISC1 back in also restored the reduced protein levels. The findings demonstrate that the co-aggregation of DISC1 caused the abnormalities in the model mice, suggesting that the co-aggregation of DISC1 with TDP-43 may disrupt cellular function and trigger psychiatric manifestations.

"DISC1 has long been a focus of research as a consequence of its implication in the heritable risk for schizophrenia," said John Krystal, MD, Editor of Biological Psychiatry. "However, this new study implicates DISC1 in the biology of FTLD. There are still unanswered questions about whether DISC1 is disrupted in association with schizophrenia risk. However, the new study by Dr. Endo and colleagues provides a compelling case for further exploring the role of this protein in frontotemporal dementia," he added.

###

Notes for editors

The article is "TDP-43 and DISC1 Co-Aggregation Disrupts Dendritic Local Translation and Mental Function in FTLD," by Ryo Endo, Noriko Takashima, Yoko Nekooki-Machida, Yusuke Komi, Kelvin Kai-Wan Hui, Masaki Takao, Hiroyasu Akatsu, Shigeo Murayama, Akira Sawa, and Motomasa Tanaka (https://doi.org/10.1016/j.biopsych.2018.03.008. It appears in Biological Psychiatry, published by Elsevier.)

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected] or +1 214 648 0880. Journalists wishing to interview the authors may contact Motomasa Tanaka at [email protected].

The authors' affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.

About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th out of 142 Psychiatry titles and 10th out of 258 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2016 Impact Factor score for Biological Psychiatry is 11.412. http://www.sobp.org/journal

About Elsevier

Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.elsevier.com

Media contact
Rhiannon Bugno
Editorial Office, Biological Psychiatry
+1 214 648 0880
[email protected]

Media Contact

Rhiannon Bugno
[email protected]
214-648-0880
@elseviernews

http://www.elsevier.com

https://www.elsevier.com/about/press-releases/research-and-journals/a-new-mechanism-for-neurodegeneration-in-a-form-of-dementia

Related Journal Article

http://dx.doi.org/10.1016/j.biopsych.2018.03.008

Share12Tweet7Share2ShareShareShare1

Related Posts

Prioritizing Genes Linked to Sudden Unexplained Death

September 16, 2025

Evaluating Sarcopenia Risk in Israel’s Older Population

September 16, 2025

Stigma in Notes Hinders Substance Disclosure in Pregnancy

September 16, 2025

Study Identifies Population Aging as Key Driver of Musculoskeletal Disorders

September 16, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    66 shares
    Share 26 Tweet 17
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Boosting Immunotherapy in Advanced Prostate Cancer

Prioritizing Genes Linked to Sudden Unexplained Death

Natural Extracts Combat Beetle Infestation in Okra

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.